WO2005082928A3 - Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite - Google Patents
Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite Download PDFInfo
- Publication number
- WO2005082928A3 WO2005082928A3 PCT/GB2005/000710 GB2005000710W WO2005082928A3 WO 2005082928 A3 WO2005082928 A3 WO 2005082928A3 GB 2005000710 W GB2005000710 W GB 2005000710W WO 2005082928 A3 WO2005082928 A3 WO 2005082928A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gip
- diabetes
- treatment
- peptide analogues
- obesity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2557151A CA2557151C (fr) | 2004-02-25 | 2005-02-25 | Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite |
JP2007500292A JP2008500280A (ja) | 2004-02-25 | 2005-02-25 | 糖尿病、インスリン抵抗性、及び肥満症の治療のためのgipペプチド・アナログ |
AU2005217198A AU2005217198A1 (en) | 2004-02-25 | 2005-02-25 | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
EP05717793A EP1730188A2 (fr) | 2004-02-25 | 2005-02-25 | Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite |
US11/090,787 US20050272652A1 (en) | 1999-03-29 | 2005-03-25 | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
US11/713,892 US7875587B2 (en) | 1999-03-29 | 2007-03-05 | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
US11/825,293 US20080009603A1 (en) | 1999-03-29 | 2007-07-03 | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0404124.0A GB0404124D0 (en) | 2004-02-25 | 2004-02-25 | Antagonists of GIP |
GB0404124.0 | 2004-02-25 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/090,787 Continuation-In-Part US20050272652A1 (en) | 1999-03-29 | 2005-03-25 | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005082928A2 WO2005082928A2 (fr) | 2005-09-09 |
WO2005082928A3 true WO2005082928A3 (fr) | 2005-12-01 |
Family
ID=32050802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2005/000710 WO2005082928A2 (fr) | 1999-03-29 | 2005-02-25 | Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1730188A2 (fr) |
JP (1) | JP2008500280A (fr) |
AU (1) | AU2005217198A1 (fr) |
CA (1) | CA2557151C (fr) |
GB (1) | GB0404124D0 (fr) |
WO (1) | WO2005082928A2 (fr) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8900593B2 (en) | 2007-02-15 | 2014-12-02 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US8980830B2 (en) | 2007-10-30 | 2015-03-17 | Indiana University Research And Technology Corporation | Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity |
US9018164B2 (en) | 2005-11-07 | 2015-04-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
US9150632B2 (en) | 2009-06-16 | 2015-10-06 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
US9156902B2 (en) | 2011-06-22 | 2015-10-13 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9249206B2 (en) | 2010-12-22 | 2016-02-02 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
US9309301B2 (en) | 2011-06-22 | 2016-04-12 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9487571B2 (en) | 2010-01-27 | 2016-11-08 | Indiana University Research And Technology Corporation | Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ554386A (en) | 2004-10-25 | 2009-12-24 | Cytos Biotechnology Ag | Gastric inhibtory polypeptide (GIP) antigen arrays with VLPs and uses thereof |
AU2006289259A1 (en) * | 2005-09-08 | 2007-03-15 | Uutech Limited | Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function |
US20090170762A1 (en) * | 2005-09-08 | 2009-07-02 | Uutech Limited | Treatment of Diabetes Related Obesity |
CA2660835A1 (fr) * | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | Analogue du gip et polypeptides hybrides possedant des proprietes selectives |
SG177953A1 (en) | 2007-01-05 | 2012-02-28 | Univ Indiana Res & Tech Corp | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
GB0717388D0 (en) * | 2007-09-07 | 2007-10-17 | Uutech Ltd | Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission |
ES2509883T3 (es) | 2007-10-30 | 2014-10-20 | Indiana University Research And Technology Corporation | Antagonistas de glucagón |
EP2224945B1 (fr) * | 2007-11-23 | 2012-05-16 | Michael Rothkopf | Procédés d'amplification de la résolution d'un diabète |
AU2009260302B2 (en) | 2008-06-17 | 2014-10-23 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
CN102088989B (zh) | 2008-06-17 | 2014-11-26 | 印第安纳大学研究及科技有限公司 | 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物 |
JP6108659B2 (ja) | 2008-06-17 | 2017-04-05 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | 代謝疾患および肥満の治療のためのgipに基づいた混合アゴニスト |
GB0814068D0 (en) * | 2008-08-01 | 2008-09-10 | Univ Ulster | Active immunisation against GIP |
KR20130133103A (ko) * | 2008-08-07 | 2013-12-05 | 입센 파마 에스.에이.에스 | N-말단이 변형된 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드(gip)의 유사체 |
EP2915538A3 (fr) * | 2008-08-07 | 2015-10-14 | Ipsen Pharma S.A.S. | Analogues tronqués de polypeptide insulinotrope glucose-dépendant |
EP2328922A4 (fr) | 2008-08-07 | 2013-01-02 | Ipsen Pharma Sas | Analogues de polypeptide insulinotrope glucose-dépendant |
CA2732973A1 (fr) | 2008-08-07 | 2010-02-11 | Ipsen Pharma S.A.S. | Analogues de polypeptide insulinotrope glucose-dependant |
PE20120332A1 (es) | 2008-12-19 | 2012-04-14 | Univ Indiana Res & Tech Corp | Profarmacos de peptido de la superfamilia de glucagon basado en amida |
JP5576694B2 (ja) * | 2009-04-10 | 2014-08-20 | 花王株式会社 | Gip上昇抑制剤 |
US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
EP2569000B1 (fr) | 2010-05-13 | 2017-09-27 | Indiana University Research and Technology Corporation | Peptides de la superfamille des glucagons présentant une activité de récepteur nucléaire d'hormone |
WO2011143208A1 (fr) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Peptides de la superfamille du glucagon manifestant une activité de récepteur couplé à une protéine g |
US9023986B2 (en) * | 2010-10-25 | 2015-05-05 | Hoffmann-La Roche Inc. | Glucose-dependent insulinotropic peptide analogs |
EP2718317B1 (fr) | 2011-06-10 | 2018-11-14 | Beijing Hanmi Pharmaceutical Co., Ltd. | Analogues de polypeptides insulinotropes dépendants du glucose, compositions pharmaceutiques et son utilisation |
US8859491B2 (en) | 2011-11-17 | 2014-10-14 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
JP6311708B2 (ja) | 2012-06-21 | 2018-04-18 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | Gip受容体活性を示すグルカゴンアナローグ |
RU2716985C2 (ru) | 2014-10-29 | 2020-03-17 | Зилэнд Фарма А/С | Соединения-агонисты gip и способы |
JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
BR112019025195A8 (pt) * | 2017-05-31 | 2020-07-07 | Univ Copenhagen | análogos do peptídeo gip de ação prolongada |
TWI770085B (zh) * | 2017-11-21 | 2022-07-11 | 日商武田藥品工業股份有限公司 | 胜肽化合物 |
US11633459B2 (en) | 2018-05-04 | 2023-04-25 | Novo Nordisk A/S | GIP derivatives and uses thereof |
CN113827706B (zh) * | 2021-09-27 | 2023-12-26 | 南通大学 | Gip及其衍生肽作为制备皮肤创伤治疗药物中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000058360A2 (fr) * | 1999-03-29 | 2000-10-05 | Uutech Limited | Peptide |
-
2004
- 2004-02-25 GB GBGB0404124.0A patent/GB0404124D0/en not_active Ceased
-
2005
- 2005-02-25 EP EP05717793A patent/EP1730188A2/fr not_active Withdrawn
- 2005-02-25 JP JP2007500292A patent/JP2008500280A/ja active Pending
- 2005-02-25 AU AU2005217198A patent/AU2005217198A1/en not_active Abandoned
- 2005-02-25 WO PCT/GB2005/000710 patent/WO2005082928A2/fr active Application Filing
- 2005-02-25 CA CA2557151A patent/CA2557151C/fr active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000058360A2 (fr) * | 1999-03-29 | 2000-10-05 | Uutech Limited | Peptide |
Non-Patent Citations (2)
Title |
---|
IRWIN NIGEL ET AL: "A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes.", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. SEP 2005, vol. 314, no. 3, September 2005 (2005-09-01), pages 1187 - 1194, XP008052103, ISSN: 0022-3565 * |
See also references of EP1730188A2 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9018164B2 (en) | 2005-11-07 | 2015-04-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
US8900593B2 (en) | 2007-02-15 | 2014-12-02 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9447162B2 (en) | 2007-02-15 | 2016-09-20 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US8980830B2 (en) | 2007-10-30 | 2015-03-17 | Indiana University Research And Technology Corporation | Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity |
US9150632B2 (en) | 2009-06-16 | 2015-10-06 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
US9487571B2 (en) | 2010-01-27 | 2016-11-08 | Indiana University Research And Technology Corporation | Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
US9249206B2 (en) | 2010-12-22 | 2016-02-02 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
US9156902B2 (en) | 2011-06-22 | 2015-10-13 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9309301B2 (en) | 2011-06-22 | 2016-04-12 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
Also Published As
Publication number | Publication date |
---|---|
CA2557151C (fr) | 2015-02-17 |
JP2008500280A (ja) | 2008-01-10 |
GB0404124D0 (en) | 2004-03-31 |
EP1730188A2 (fr) | 2006-12-13 |
CA2557151A1 (fr) | 2005-09-09 |
AU2005217198A1 (en) | 2005-09-09 |
WO2005082928A2 (fr) | 2005-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005082928A3 (fr) | Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite | |
WO2000058360A3 (fr) | Peptide | |
NL301089I1 (fr) | ||
WO2006024275A3 (fr) | Invention concernant le glp-1 et l'exendine | |
TW200616657A (en) | Therapeutic peptides and method | |
MX2009002999A (es) | Analogos de insulina resistentes a proteasa. | |
WO2003082898A3 (fr) | Nouveaux analogues du polypeptide insulinotropiquedependant du glucose (gip) | |
WO2007044591A3 (fr) | Produits pharmaceutiques a base de polypeptides intestinaux vasoactifs | |
WO2006053043A3 (fr) | Methodes de traitement du diabete sucre | |
WO2006042152A3 (fr) | Produits pharmaceutiques a base de polypeptides intestinaux vasoactifs | |
WO2006127757A3 (fr) | Fusion interferon-igg | |
TW200744642A (en) | Novel peptides for use in the treatment of obesity | |
WO2007028633A3 (fr) | Traitement de l'obesite associee aux diabetes | |
TW200507870A (en) | GLP-1 analog fusion proteins | |
EP1756074A4 (fr) | Derives de 1,2,4-oxadiazole en tant qu'inhibiteurs de la dipeptidylpeptidase-iv dans le traitement ou la prevention de diabetes | |
WO2007019865A3 (fr) | Traitement au moyen de peptides de liaison cd4 et par rayonnements | |
WO2004096854A3 (fr) | Analogues de l'insuline ayant une action prolongee | |
WO2009014650A3 (fr) | Exotoxines recombinantes de vibrio cholerae | |
WO2010054326A3 (fr) | Fragments c-terminaux du peptide 1 de type glucagon (glp-1) | |
WO2008087186A3 (fr) | Nouveaux peptides pour le traitement de l'obésité | |
EA200801180A1 (ru) | Селективные пептидные агонисты рецептора vpac2 | |
WO2006048450A3 (fr) | Nouveaux peptides utiles dans le traitement de l'obesite | |
WO2006048452A3 (fr) | Nouveaux peptides utiles dans le traitement de l'obesite | |
WO2004050115A3 (fr) | Polytherapie mettant en oeuvre des exendines et des thiazolidinediones | |
WO2007030519A3 (fr) | Analogues de glp-1 stabilises |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 11090787 Country of ref document: US |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005217198 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2557151 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007500292 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2005217198 Country of ref document: AU Date of ref document: 20050225 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005217198 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005717793 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005717793 Country of ref document: EP |